How Regulatory CD25+CD4+ T Cells Impinge on Tumor Immunobiology: The Differential Response of Tumors to Therapies

Aiming to get a better insight on the impact of regulatory CD25+CD4+ T cells in tumor-immunobiology, a simple mathematical model was previously formulated and studied. This model predicts the existence of two alternative modes of uncontrolled tumor growth, which differ on their coupling with the immune system, providing a plausible explanation to the observation that the development of some tumors expand regulatory T cells whereas others do not. We report now the study of how these two tumor classes respond to different therapies, namely vaccination, immune suppression, surgery, and their different combinations. We show 1) how the timing and the dose applied in each particular treatment determine whether the tumor will be rejected, with or without concomitant autoimmunity, or whether it will continue progressing with slower or faster pace; 2) that both regulatory T cell-dependent and independent tumors are equally sensitive to vaccination, although the former are more sensitive to T cell depletion treatments and are unresponsive to partial surgery alone; 3) that surgery, suppression, and vaccination treatments, can synergistically improve their individual effects, when properly combined. Particularly, we predict rational combinations helping to overcome the limitation of these individual treatments on the late stage of tumor development.

[1]  R. Schreiber,et al.  Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells , 2005, The Journal of experimental medicine.

[2]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[3]  K. Knutson,et al.  Cancer Immunol Immunother DOI 10.1007/s00262-006-0194-y REVIEW , 2006 .

[4]  Lisette G de Pillis,et al.  A validated mathematical model of cell-mediated immune response to tumor growth. , 2007, Cancer research.

[5]  A. Potti,et al.  Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future , 2006, Expert opinion on biological therapy.

[6]  T. Fujita,et al.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.

[7]  A. Radunskaya,et al.  Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations , 2022 .

[8]  Hailing Lu,et al.  IL-2 Immunotoxin Therapy Modulates Tumor-Associated Regulatory T Cells and Leads to Lasting Immune-Mediated Rejection of Breast Cancers in neu-Transgenic Mice1 , 2006, The Journal of Immunology.

[9]  H. Fujii,et al.  CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers , 2006, Cancer Immunology, Immunotherapy.

[10]  K. Eguchi,et al.  Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. , 2006, Oncology reports.

[11]  B. Chauffert,et al.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.

[12]  C. Drake,et al.  Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. , 2006, Blood.

[13]  Mark A J Chaplain,et al.  Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour. , 2004, Mathematical medicine and biology : a journal of the IMA.

[14]  A. Houghton,et al.  Autoimmunity and tumor immunity induced by immune responses to mutations in self , 2006, Nature Medicine.

[15]  T. Elliott,et al.  The influence of CD25+ cells on the generation of immunity to tumour cell lines in mice. , 2004, Novartis Foundation symposium.

[16]  Dominik Wodarz,et al.  A dynamical perspective of CTL cross-priming and regulation: implications for cancer immunology. , 2003, Immunology letters.

[17]  M. Beyer,et al.  Regulatory T cells in cancer. , 2006, Blood.

[18]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[19]  H. Ikeda,et al.  CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Abdullah,et al.  Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. , 2006, Immunology letters.

[21]  C. June,et al.  Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma , 2005, Cancer biology & therapy.

[22]  E. Tartour,et al.  Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers , 2006, Clinical Cancer Research.

[23]  H. Frieboes,et al.  An integrated computational/experimental model of tumor invasion. , 2006, Cancer research.

[24]  S. Sakaguchi,et al.  Regulatory T cells in immune surveillance and treatment of cancer. , 2006, Seminars in cancer biology.

[25]  Azuma Ohuchi,et al.  A Mathematical Analysis of the Interactions between Immunogenic Tumor Cells and Cytotoxic T Lymphocytes , 2001, Microbiology and immunology.

[26]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[27]  Jorge Carneiro,et al.  Three-Cell Interactions in T Cell-Mediated Suppression? A Mathematical Analysis of Its Quantitative Implications1 , 2001, The Journal of Immunology.

[28]  Hiroshi Tanaka,et al.  Depletion of CD4+CD25+ Regulatory Cells Augments the Generation of Specific Immune T Cells in Tumor-Draining Lymph Nodes , 2002, Journal of immunotherapy.

[29]  H. Fiegl,et al.  The Expression of the Regulatory T Cell–Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer , 2005, Clinical Cancer Research.

[30]  K. L. Monzón A quantitative approach to dominant tolerance , 2002 .

[31]  J. Chin,et al.  Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer. , 2006, The Canadian journal of urology.

[32]  C. van den Dool,et al.  When three is not a crowd: a Crossregulation Model of the dynamics and repertoire selection of regulatory CD4+ T cells , 2007, Immunological reviews.

[33]  Jorge Carneiro,et al.  How regulatory CD25(+)CD4(+) T cells impinge on tumor immunobiology? On the existence of two alternative dynamical classes of tumors. , 2007, Journal of theoretical biology.

[34]  鬼塚 正三郎 Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody , 1999 .

[35]  Weiguo Lu,et al.  Proportion of CD4+CD25+ Regulatory T Cell is Increased in the Patients with Ovarian Carcinoma , 2005, Cancer investigation.

[36]  H. Mellstedt,et al.  Clinical results of vaccine therapy for cancer: learning from history for improving the future. , 2006, Advances in cancer research.

[37]  Zvia Agur,et al.  Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. , 2006, Cancer research.

[38]  N. Egilmez,et al.  Chronic Immune Therapy Induces a Progressive Increase in Intratumoral T Suppressor Activity and a Concurrent Loss of Tumor-Specific CD8+ T Effectors in her-2/neu Transgenic Mice Bearing Advanced Spontaneous Tumors1 , 2006, The Journal of Immunology.

[39]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[40]  J. Carneiro,et al.  Modelling T-cell-mediated suppression dependent on interactions in multicellular conjugates. , 2000, Journal of theoretical biology.

[41]  K. Matsushima,et al.  Visualization of naturally occurring Foxp3+ regulatory T cells in normal and tumor-bearing mice. , 2004, International immunopharmacology.

[42]  Benedetto Piccoli,et al.  Optimal Control in a Model of Dendritic Cell Transfection Cancer Immunotherapy , 2006, 2004 43rd IEEE Conference on Decision and Control (CDC) (IEEE Cat. No.04CH37601).

[43]  C. June,et al.  Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 , 2002, The Journal of Immunology.

[44]  S. Fox,et al.  The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia‐inducible factor (HIF)‐2α but not HIF‐1α , 2007, The Prostate.

[45]  B. Moss,et al.  Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Youjin Lee,et al.  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors , 2005, The Journal of experimental medicine.

[47]  L. Old,et al.  Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  P. Watson,et al.  Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. , 2007, Cancer research.

[49]  S. Kim-Schulze,et al.  Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.